Glaukos (NYSE:GKOS) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Glaukos (NYSE:GKOS) from a hold rating to a buy rating in a research report released on Saturday morning.

A number of other equities analysts have also recently commented on GKOS. JPMorgan Chase & Co. lifted their price objective on shares of Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday. Stifel Nicolaus set a $170.00 target price on Glaukos in a report on Thursday. Citigroup lifted their target price on Glaukos from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a report on Tuesday, April 21st. Finally, William Blair raised Glaukos to a “strong-buy” rating in a report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $138.85.

Glaukos Trading Down 2.3%

GKOS stock opened at $140.38 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.06. The company has a fifty day moving average price of $114.02 and a two-hundred day moving average price of $107.85. Glaukos has a one year low of $73.16 and a one year high of $146.75. The stock has a market cap of $8.22 billion, a price-to-earnings ratio of -42.80 and a beta of 0.94.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The firm had revenue of $150.57 million during the quarter, compared to analysts’ expectations of $137.00 million. During the same period in the previous year, the business posted ($0.22) earnings per share. The company’s revenue for the quarter was up 41.2% compared to the same quarter last year. Equities analysts anticipate that Glaukos will post -0.6 EPS for the current year.

Insider Transactions at Glaukos

In related news, Director Aimee S. Weisner sold 15,000 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $117.38, for a total value of $1,760,700.00. Following the completion of the transaction, the director owned 18,806 shares of the company’s stock, valued at $2,207,448.28. The trade was a 44.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Alex R. Thurman sold 2,511 shares of the business’s stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total value of $267,321.06. Following the completion of the transaction, the chief financial officer directly owned 41,967 shares of the company’s stock, valued at approximately $4,467,806.82. This trade represents a 5.65% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 19,657 shares of company stock valued at $2,250,060. 5.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Fifth Third Bancorp raised its stake in Glaukos by 318.0% in the first quarter. Fifth Third Bancorp now owns 16,533 shares of the medical instruments supplier’s stock valued at $1,780,000 after purchasing an additional 12,578 shares in the last quarter. Sequoia Financial Advisors LLC raised its stake in Glaukos by 15.6% in the first quarter. Sequoia Financial Advisors LLC now owns 2,077 shares of the medical instruments supplier’s stock valued at $224,000 after purchasing an additional 281 shares in the last quarter. Stephens Inc. AR acquired a new position in Glaukos in the first quarter valued at about $363,000. Elevation Point Wealth Partners LLC acquired a new position in Glaukos in the first quarter valued at about $247,000. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Glaukos in the first quarter valued at about $1,007,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Q1 results and outlook: Glaukos reported a Q1 revenue beat, 41% year-over-year growth, narrower loss and a raised 2026 revenue outlook — the key fundamental catalyst supporting the stock. Zacks: Q1 Earnings Beat & Raised Outlook
• Positive Sentiment: Analyst upgrades: Multiple firms raised ratings/targets after the quarter — BTIG bumped its target to $141 (buy), Wells Fargo to $138 (overweight), JPMorgan to $140 (overweight) and Needham raised its target — these actions validate the quarter’s strength and support further investor interest. BTIG Research PT Raise
• Neutral Sentiment: Analyst target mix: although several firms raised targets and ratings, many new targets are close to the current price, implying limited near-term upside from those specific forecasts. Wells Fargo PT Raise
• Neutral Sentiment: Market reaction nuance: after the after-hours jump, some intraday profit-taking is common when a stock has run up; elevated volume today suggests active repositioning by traders. OCBJ: After-Hours Move
• Negative Sentiment: Some revised price targets are below the current market price (e.g., Needham and others), which can encourage short-term selling or cap upside until guidance and execution confirm sustained growth. Needham PT Update

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.